These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32033908)

  • 21. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
    Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study.
    Silva R; Berta A; Larsen M; Macfadden W; Feller C; Monés J;
    Ophthalmology; 2018 Jan; 125(1):57-65. PubMed ID: 28893454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration.
    Schmidt-Erfurth U; Bogunovic H; Sadeghipour A; Schlegl T; Langs G; Gerendas BS; Osborne A; Waldstein SM
    Ophthalmol Retina; 2018 Jan; 2(1):24-30. PubMed ID: 31047298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kim JH; Kim CG; Lee DW; Yoo SJ; Lew YJ; Cho HJ; Kim JY; Lee SH; Kim JW
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):107-116. PubMed ID: 31741044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
    Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
    Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Results of Full Macular Translocation for Choroidal Neovascularization in Age-Related Macular Degeneration.
    van Romunde SH; Polito A; Bertazzi L; Guerriero M; Pertile G
    Ophthalmology; 2015 Jul; 122(7):1366-74. PubMed ID: 25881514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy.
    Wykoff CC; Rosenfeld PJ; Waheed NK; Singh RP; Ronca N; Slakter JS; Staurenghi G; Monés J; Baumal CR; Saroj N; Metlapally R; Ribeiro R
    Ophthalmology; 2021 Sep; 128(9):1325-1336. PubMed ID: 33711380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
    Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
    Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.
    Vardarinos A; Gupta N; Janjua R; Iron A; Empeslidis T; Tsaousis KT
    BMC Ophthalmol; 2017 Apr; 17(1):58. PubMed ID: 28449645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
    Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial.
    Feltgen N; Bertelmann T; Bretag M; Pfeiffer S; Hilgers R; Callizo J; Goldammer L; Bemme S; Hoerauf H
    Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):923-934. PubMed ID: 28102456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CUTICULAR DRUSEN: Risk of Geographic Atrophy and Macular Neovascularization.
    Sakurada Y; Parikh R; Gal-Or O; Balaratnasingam C; Leong BCS; Tanaka K; Cherepanoff S; Spaide RF; Freund KB; Yannuzzi LA
    Retina; 2020 Feb; 40(2):257-265. PubMed ID: 31972795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.
    Chang W; Garg SJ; Maturi R; Hsu J; Sivalingam A; Gupta SA; Regillo CD; Ho AC
    Am J Ophthalmol; 2014 Jun; 157(6):1250-7. PubMed ID: 24531021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study.
    Jackson TL; Boyer D; Brown DM; Chaudhry N; Elman M; Liang C; O'Shaughnessy D; Parsons EC; Patel S; Slakter JS; Rosenfeld PJ
    JAMA Ophthalmol; 2017 Jul; 135(7):761-767. PubMed ID: 28570723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LONG-TERM RESULTS OF AUTOLOGOUS RETINAL PIGMENT EPITHELIUM AND CHOROID TRANSPLANTATION FOR THE TREATMENT OF EXUDATIVE AND ATROPHIC MACULOPATHIES.
    Parolini B; Di Salvatore A; Pinackatt SJ; Baldi A; Besozzi G; Finzi A; Cardillo D; Sallam AB; Frisina R
    Retina; 2020 Mar; 40(3):507-520. PubMed ID: 30608346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
    JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.